- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Global Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
59
0 new
High return on equity, past performance and sound balance sheet.
59 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
500488 | ₹28,637.70 | -0.07% | 26.8% | ₹608.5b | ₹28,331.43 | PE47.4x | E10.9% | 1.4% | ||
ORNBV | €42.78 | 2.2% | 8.9% | €6.0b | €50.00 | PE18.1x | E9.7% | 3.8% | ||
688278 | CN¥70.91 | 4.5% | 37.9% | CN¥28.8b | CN¥85.76 | PE38.9x | E32.0% | 0.6% | ||
500420 | ₹3,434.25 | 2.6% | 55.0% | ₹1.2t | ₹3,591.55 | PE64.5x | E22.6% | 0.8% | ||
600285 | CN¥22.87 | 5.5% | 38.2% | CN¥12.9b | CN¥30.05 | PE19.1x | E16.1% | 3.5% | ||
MEDP | US$337.28 | -2.5% | 8.2% | US$10.4b | US$347.92 | PE28.6x | E10.8% | n/a | ||
300896 | CN¥205.18 | -2.8% | 4.1% | CN¥61.8b | CN¥266.90 | PE30.5x | E16.5% | 0% | ||
300705 | CN¥23.88 | -8.9% | -0.8% | CN¥11.8b | CN¥33.10 | PE23.2x | E25.5% | 1.0% | ||
4015 | ر.س156.20 | -0.5% | 47.9% | ر.س10.9b | ر.س174.38 | PE31.3x | E11.1% | 2.0% | ||
1681 | HK$7.79 | -0.1% | 66.5% | HK$6.5b | HK$10.20 | PE7.3x | E14.7% | 7.4% | ||
AJANTPHARM | ₹2,866.45 | 2.1% | 45.6% | ₹358.0b | ₹2,973.91 | PE40.9x | E16.4% | 2.0% | ||
688578 | CN¥61.59 | -4.3% | 49.5% | CN¥27.7b | CN¥75.00 | PE21.4x | E18.4% | 0.8% | ||
EZZ | AU$2.91 | 10.2% | 381.0% | AU$134.3m | AU$5.45 | PE19.3x | E17.9% | 1.0% | ||
1795 | NT$260.50 | -0.2% | -2.4% | NT$69.1b | NT$398.80 | PE15.9x | E22.3% | 1.8% | ||
A001060 | ₩23,550.00 | -0.6% | -36.0% | ₩589.1b | ₩41,500.00 | PE8.3x | E14.6% | 1.7% | ||
4587 | JP¥2,570.00 | -4.6% | 94.8% | JP¥333.1b | JP¥3,442.86 | PE19.5x | E0.1% | n/a | ||
600436 | CN¥220.50 | -1.3% | -6.4% | CN¥133.0b | CN¥277.61 | PE43.2x | E15.9% | 1.1% | ||
ACAD | US$16.87 | -2.3% | -46.3% | US$2.8b | US$25.11 | PE21.8x | E28.0% | n/a | ||
3933 | HK$11.30 | -4.7% | 72.0% | HK$20.5b | HK$12.09 | PE6.6x | E5.0% | 5.2% | ||
NEU | AU$12.14 | -8.9% | -49.5% | AU$1.6b | AU$26.21 | PE13.2x | E-9.9% | n/a | ||
EXEL | US$33.29 | -5.0% | 39.1% | US$9.6b | US$33.06 | PE20.4x | E15.8% | n/a | ||
NATCOPHARM | ₹1,416.95 | -1.7% | 78.9% | ₹253.8b | ₹1,337.27 | PE13x | E-20.1% | 0.4% | ||
4519 | JP¥6,650.00 | 0.8% | 25.1% | JP¥10.9t | JP¥7,416.67 | PE28.3x | E5.9% | 1.2% | ||
CPRX | US$21.27 | -0.5% | 28.3% | US$2.6b | US$32.25 | PE17.8x | E17.5% | n/a |